Table 1.
Clinicopathological characteristics of the cases n (%)
| Characteristics | n = 146 |
| Age (yr) | 64.2 ± 10.1 |
| 36-60 | 49 (33.6) |
| 61-70 | 51 (34.9) |
| 71-82 | 46 (31.5) |
| Gender | |
| Male | 105 (72.0) |
| Female | 41 (28.0) |
| Viral infection | |
| HBV | 32 (22.0) |
| HCV | 98 (67.1) |
| NonB nonC | 16 (10.9) |
| Child-Pugh classification | |
| A | 139 (95.2) |
| B | 7 (4.8) |
| C | 0 (0) |
| Background liver tissue | |
| Normal | 4 (2.8) |
| Chronic hepatitis | 56 (39.7) |
| Liver cirrhosis | 81 (57.5) |
| Tumor size (mm) | 27.3 ± 25.4 |
| 8-10 | 7 (4.8) |
| 11-20 | 78 (53.4) |
| 21-30 | 29 (19.9) |
| 31-250 | 32 (21.9) |
| Differentiation | |
| Well | 33 (22.6) |
| Moderate | 93 (63.7) |
| Poor | 20 (13.7) |
| Pseudoglandular pattern | |
| Absent | 97 (66.4) |
| Present | 49 (33.6) |
| Nuclear grade | |
| Low | 116 (79.5) |
| High | 30 (20.5) |
| Fatty change | |
| Absent | 121 (82.9) |
| Present | 25 (17.1) |
| Inflammation | |
| Absent | 75 (51.4) |
| Present | 71 (48.6) |
| Fibrosis | |
| Absent | 104 (71.2) |
| Present | 42 (28.8) |
| Cholestasis | |
| Absent | 95 (65.0) |
| Present | 51 (35.0) |
| Tumor stage | |
| 1 | 65 (44.5) |
| 2 | 61 (41.8) |
| 3 | 16 (11.0) |
| 4 | 4 (2.7) |
| L-FABP immunostaining | |
| Negative | 16 (10.9) |
| Positive | 130 (89.1) |
| CK 7 immunostaining | |
| Negative | 68 (46.6) |
| Positive | 78 (53.4) |
| CK 19 immunostaining | |
| Negative | 136 (93.2) |
| Positive | 10 (6.8) |
| β-catenin immunostaining | |
| Negative | 101 (69.2) |
| Positive | 45 (30.8) |
| GS immunostaining | |
| Negative | 110 (75.3) |
| Positive | 36 (24.7) |
| SAA immunostaining | |
| Negative | 136 (93.2) |
| Positive | 10 (6.8) |
HBV: Hepatitis B virus; HCV: Hepatitis C virus; L-FABP: Liver fatty acid-binding protein; CK: Cytokeratin; GS: Glutamine synthetase; SAA: Serum amyloid A. Background liver tissue could not be evaluated in five cases.